References

Aussedat, J., A. Ray and L. Kay, 2006. Improvement of long term preservation of isolated arrested heart: Beneficial effect of ant ischemic agent trimetazidine. J. Cardiovasc. Pharmacol., 21: 128-128.

Boudina, S. and E.D. Abel, 2007. Diabetic cardiomyopathy revisited. Circulation, 115: 3213-3223.
PubMed  |  Direct Link  |  

Carley, A.N. and D.L. Severson, 2005. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim. Biophys. Acta., 1734: 112-126.
PubMed  |  

Chen, X.P., W.Y. Yang, S. Bu, J.Z. Xiao, X.L. Liu, N. Wang and W.H. Zhao, 2004. Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats. Zhonghua Nei Ke Xue Za Zhi, 43: 280-283.
PubMed  |  

Dyntar, D., M. Eppenberger-Eberhardt, K. Maedler, M. Pruschy, H.M. Eppenberger, G.A. Spinas and M.Y. Donath, 2001. Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes, 50: 2105-2113.
CrossRef  |  Direct Link  |  

Fang, Z.Y., J.B. Prins and T.H. Marwick, 2004. Diabetic cardiomyopathy: Evidence, mechanisms and therapeutic implications. Endocr. Rev., 25: 543-567.
PubMed  |  

Farhangkhoee, H., Z.A. Khan, S. Chen and S. Chakrabarti, 2006. Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutrit. Metab., 10.1186/1743-7075-3-27

Finck, B.N., X. Han, M. Courtois, F. Aimond and J.M. Nerbonne et al., 2003. A critical role for PPAR α-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content. Proc. Natl. Acad. Sci., 100: 1226-1231.
CrossRef  |  PubMed  |  Direct Link  |  

How, O.J., E. Aasum, D.L. Severson, W.Y. Chan, M.F. Essop and T.S. Larsen, 2006. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes, 55: 466-473.
PubMed  |  

Lefebvre, P., G. Chinetti, J.C. Fruchart and B. Staels, 2006. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J. Clin. Invest., 116: 571-580.
Direct Link  |  

Matsuzawa, Y., 2006. The metabolic syndrome and adipocytokines. FEBS Lett., 580: 2917-2921.
PubMed  |  

Poornima, I.G., P. Parikh and R.P. Shannon, 2006. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ. Res., 98: 596-605.
PubMed  |  Direct Link  |  

Rosano, G.M., C. Vitale, B. Sposato, G. Mercuro and M. Fini, 2003. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: A double-blind placebo-controlled study. Cardiovasc. Diabetol., 2: 16-16.
CrossRef  |  PubMed  |  

Tabbi-Anneni, I., C. Helies-Toussaint, D. Morin, A. Bescond-Jacquet, A. Lucien and A. Grynberg, 2003. Prevention of heart failure in rats by trimetazidine treatment: A consequence of accelerated phospholipid turnover? J. Pharmacol. Exp. Ther. Fast Forward, 304: 1003-1009.
PubMed  |  

Young, M.E., F.A. Laws, G.W. Goodwin and H. Taegtmeyer, 2001. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem., 276: 44390-44395.
Direct Link  |